Halozyme Therapeutics Inc (NAS:HALO)
$ 61.49 0.51 (0.84%) Market Cap: 7.82 Bil Enterprise Value: 8.62 Bil PE Ratio: 20.36 PB Ratio: 17.27 GF Score: 90/100

Halozyme Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript

Sep 28, 2021 / 05:20PM GMT
Release Date Price: $38.53 (-4.03%)
Charles Cliff Duncan
Cantor Fitzgerald & Co., Research Division - Senior Analyst

Hello. Welcome to the Cantor Global Healthcare Conference for 2021. My name is Charles Duncan. I'm a Managing Director and Senior Biotechnology Analyst with the firm's equity research department. And this is day 2 of the annual event. And I have to say, what a year it has been since we last hosted clients at the 2020 Cantor conference, a year ago or so. It's a pleasure to introduce the next presenting speaker that is -- or the company is called Halozyme. And the speaker is Elaine Sun. Elaine is the company's CFO. Hi, Elaine, good to see you.

Elaine D. Sun
Halozyme Therapeutics, Inc. - Senior VP & CFO

Hi, Charles, so nice to be with you today.

Questions & Answers

Charles Cliff Duncan
Cantor Fitzgerald & Co., Research Division - Senior Analyst

Nice to be with you as well. I'm interested to hear a lot about Halozyme, very fresh business, very differentiated. We cover it and enthusiastically so. But before we talk

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot